Afamitresgene autoleucel

艾基奥仑赛

Report date: 2026/05/08 20:02:52

Base Information

Drug NameAfamitresgene autoleucel
Drug Alias NameMAGE-A4 TCRMAGE-A4 SPEAR T-cell therapyMelanoma-associated antigen A4-specific T-cells (Adaptimmune)afami-celafamitrisgene autoleucel +[7] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector +[4] 
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsImmunomodulators +[4] 
TargetsMelanoma-associated antigen 4
Therapy Area/IndicationsSarcoma, Synovial
Global Approved IndicationsSarcoma, Synovial
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/08/01
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAdaptimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesAdaptimmune Therapeutics PlcUs Worldmeds
Inactive CompaniesN/A
Active IndicationsSarcoma, Synovial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A